Navigation Links
Nabi Biopharmaceuticals' Stockholders Approve Asset Sale
Date:11/8/2007

BOCA RATON, Fla., Nov. 8 /PRNewswire-FirstCall/ -- Nabi Biopharmaceuticals (Nasdaq: NABI) (the "Company") announced that, at today's Special Meeting of Stockholders, its stockholders voted overwhelmingly to approve the previously announced sale of assets transaction involving Biotest Pharmaceuticals Corporation and Biotest AG.

More than 60 percent of the outstanding shares of the Company's common stock were represented at the meeting and 98 percent of those shares were voted in favor of the sale of assets transaction.

"We are pleased and gratified by the strong support we have received from our stockholders and thank them for their continued commitment to Nabi Biopharmaceuticals," said Leslie Hudson, Ph.D., the Company's interim president and chief executive officer.

About Nabi Biopharmaceuticals

Nabi Biopharmaceuticals leverages its experience and knowledge in powering the immune system to develop and, in certain areas, market products that target serious medical conditions in the areas of hepatitis and transplants, gram positive bacterial infections and nicotine addiction. We are a vertically integrated company with sales of antibodies and other biologics, including Nabi-HB(R) [Hepatitis B Immune Globulin (Human)], a pipeline of products in various stages of development and a state-of-the-art manufacturing capability. The company operates through two strategic business units: Nabi Biologics and Nabi Pharmaceuticals. Nabi Biologics has responsibility for the company's protein and immunological products and development pipeline, including Nabi- HB. Nabi Pharmaceuticals is responsible for the NicVAX(R) (Nicotine Conjugate Vaccine) and StaphVAX(R) (Staphylococcus aureus Polysaccharide Conjugate Vaccine) development programs. For a complete list of pipeline products, please go to: http://www.nabi.com/pipeline/index.php. In September 2007, Nabi announced that it had entered into a definitive agreement with Biotest AG to sell the Nabi Biologics strategic business unit to Biotest Pharmaceuticals Corporation, including Nabi-HB(R) [Hepatitis B Immune Globulin (Human)], and other plasma business assets, including Nabi's state-of-the-art plasma protein production plant, and nine FDA-certified plasma collection centers across the U.S. The acquisition also will include certain of Nabi's Corporate Shared Services group assets and the company's Boca Raton, Florida headquarters and other facilities, as well as the assumption of certain liabilities, and is expected to close by the end of the year. The company is headquartered in Boca Raton, Florida. For additional information about Nabi Biopharmaceuticals, please visit our Web site: http://www.nabi.com.


'/>"/>
SOURCE Nabi Biopharmaceuticals
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
2. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
3. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
4. XTL Biopharmaceuticals Announces Presentation of Novel Pre-Clinical Inhibitors of Hepatitis C at an Upcoming International Scientific Conference
5. XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain
6. Nabi Biopharmaceuticals Announces Sale of Nabi Biologics to Biotest AG
7. Keryx Biopharmaceuticals to Present at Bank of America Investment Conference
8. Morria Biopharmaceuticals Plc Announces Appointment of Dr. Rosemary Mazanet as Interim Chief Executive Officer
9. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
10. Morria Biopharmaceuticals Plc Appoints Dr. Johnson Lau and Dr. David Sidransky to Board of Directors
11. XTL Biopharmaceuticals Ltd. AGM / EGM Postponed Until October 2, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , ... December 08, 2016 ... ... the commercial launch of flexible packaging for their exceptionally efficient human mesenchymal ... system extends RoosterBio’s portfolio of bioprocess media products engineered to radically streamline ...
(Date:12/8/2016)... 2016  Soligenix, Inc. (OTCQB: SNGX) (Soligenix or ... developing and commercializing products to treat rare diseases ... today the long-term follow-up data from its Phase ... Innate Defense Regulator (IDR), in the treatment of ... patients undergoing chemoradiation therapy (CRT).  The additional 12-month ...
(Date:12/8/2016)... Savannah River Remediation LLC group evaluated ... NT-MAX Lake & Pond Sludge and Muck ... conjunction with Hexa Armor/ Rhombo cover manufactured by ... Discharge Elimination System requirements. The Savannah ... of elevated pH levels, above 8.5, especially during ...
(Date:12/8/2016)... 2016   Biocept, Inc . (NASDAQ: ... clinically actionable liquid biopsy tests to improve the ... featuring its Target Selectorâ„¢ Circulating Tumor Cell platform ... detection of actionable biomarkers in patients with metastatic ... Sara Cannon Research Institute (SCRI), the research arm ...
Breaking Biology Technology:
(Date:12/2/2016)... 2016   SoftServe , a global digital ... an electrocardiogram (ECG) biosensor analysis system for continuous ... asset. The smart system ensures device-to-device communication between ... and mobile devices to easily ,recognize, and monitor ... vehicle technology advances, so too must the security ...
(Date:11/29/2016)... 29, 2016   Neurotechnology , a ... recognition technologies, today released FingerCell 3.0, a ... solutions that run on low-power, low-memory microcontrollers. ... less than 128KB of memory, enabling it ... have limited on-board resources, such as: mobile ...
(Date:11/22/2016)... India , November 22, 2016 According to ... (Fingerprint, IRIS, Palm Print, Face, Vein, Signature, Voice), Multi-Factor), Component (Hardware and ... 2022", published by MarketsandMarkets, the market is expected to grow from USD ... a CAGR of 16.79% between 2016 and 2022. ... ...
Breaking Biology News(10 mins):